by Gastric motility disorder drugs are used for treating gastrointestinal conditions such as gastroparesis, gastric stasis and intestinal pseudo-obstruction. These conditions involve delayed gastric emptying which hampers normal digestive tract functioning. Some common symptoms of gastric motility disorders include abdominal bloating and fullness, vomiting and nausea. Rising prevalence of gastrointestinal diseases, increasing awareness regarding digestive disorders and growing geriatric population are some of the key factors fueling the demand for gastric motility disorder drugs.
The Global Gastric Motility Disorder Drug Market is estimated to be valued at US$ 83.15 Bn in 2024 and is expected to exhibit a CAGR of 5.4% over the forecast period from 2024 to 2031.
Key Takeaways
Key players: Key players operating in the gastric motility disorder drug market are Pfizer Inc., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Boehringer Ingelheim, Eli Lilly and Company, Bristol Myers Squibb, Daiichi Sankyo Company, Limited, Bausch Health Companies, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals, Eisai Co., Ltd., Ferring Pharmaceuticals, UCB, Evoke Pharma, and Cadila Pharmaceuticals.
Key opportunities: Growing demand for novel gastric motility disorder drugs, increasing R&D investment by pharmaceutical companies and need for more effective drugs with less side effects present significant growth opportunities in the market over the forecast period.
Global expansion: Key market players are focusing on expansion in high growth emerging markets through strategic collaborations and partnerships with regional players. Moreover, various awarenss programs aimed at educating people regarding gastrointestinal disorders are also facilitating market growth in developing nations.
Market drivers: Rising geriatric population worldwide is a major driver as aging enhances the risk of developing gastrointestinal motility issues. Rapid urbanization and changing lifestyles have also increased gastrointestinal disease incidence rates globally which is propelling the gastric motility disorder drug market forward.
PEST Analysis
Political: The gastric motility disorder therapeutics market is regulated by various regulatory bodies across regions. Regulations have an influence on drug approval times, pricing, and reimbursement policies thereby impacting the overall market growth.
Economic: Rising income levels, growing healthcare spending, and the increasing demand for efficient therapeutics for gastric motility disorders are the key economic drivers boosting the gastric motility disorder therapeutics market.
Social: The rising population suffering from gastric motility disorders, enhanced awareness, and lifestyle changes are some of the important social factors fueling the demand for gastric motility disorder therapeutics.
Technological: Advancements in drug delivery technologies, development of advanced gastric motility disorder therapeutics, digital technologies for efficient disease management are some of the technological aspects having a positive influence on the market growth.
North America accounts for the major share of the global gastric motility disorder drug market in terms of value. Factors such as increasing prevalence of gastroparesis and other gastric motility disorders, growing ageing population, developed healthcare infrastructure, and high healthcare spending contribute to the dominant share of the region.
The Asia Pacific region is anticipated to witness the fastest growth over the forecast period owing to rapidly improving healthcare infrastructure, rising medical tourism, increasing healthcare spending, growing geriatric population, and the presence of emerging economies such as India, China, South Korea providing ample opportunities for market expansion.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
